Health Care • Biotechnology: Pharmaceutical Preparations
$290.79 ▲ +4.80
(+1.68%)
MKT CAP: $513.86B • VOL: 4.33M
52W L $191 52W H $299
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$244
MEDIAN
$326
MEAN
$332
HIGH
$395
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE ABBV TAPE
ABBV // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $351.86 | $334.41 | 2025-02-14 | $264.62 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $366.40 | $343.13 | 2025-02-06 | $273.34 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $331.50 | $319.87 | 2025-01-29 | $279.16 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $296.61 | — | 2025-01-17 | $284.97 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $255.90 | $276.25 | 2025-01-09 | $258.80 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $346.04 | $302.42 | 2024-12-18 | $252.99 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $282.07 | $293.70 | 2024-12-04 | $270.43 | -4.3% | 48% | C |